Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   39185   clinical trials with a EudraCT protocol, of which   6421   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2014-004027-52
    Sponsor's Protocol Code Number:GINECO-OV125b
    National Competent Authority:Belgium - FPS Health-DGM
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2015-08-24
    Trial results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedBelgium - FPS Health-DGM
    A.2EudraCT number2014-004027-52
    A.3Full title of the trial
    Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase III Trial of Olaparib vs. Placebo in Patients with Advanced High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberGINECO-OV125b
    A.5.4Other Identifiers
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorARCAGY Research
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstra-Zeneca
    B.4.2CountryUnited Kingdom
    B.4.1Name of organisation providing supportRoche
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationARCAGY-GINECO
    B.5.2Functional name of contact pointProject Manager, Syvlie Mijonnet
    B.5.3 Address:
    B.5.3.1Street Address67 rue Saint Jacques
    B.5.3.2Town/ cityParis
    B.5.3.3Post code75005
    B.5.4Telephone number+33142348323
    B.5.5Fax number+33143262673
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameolaparib
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNolaparib
    D.3.9.1CAS number 763113-22-0
    D.3.9.3Other descriptive nameOLAPARIB
    D.3.9.4EV Substance CodeSUB32234
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number600
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment
    E.1.1.1Medical condition in easily understood language
    Patients with advanced epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10070908
    E.1.2Term Ovarian cancer stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10070907
    E.1.2Term Ovarian cancer stage III
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the efficacy by progression free survival (PFS1) investigator based according to modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) of olaparib maintenance compared to placebo in high grade epithelial ovarian, fallopian tube, or peritoneal cancer that are in clinical complete response or partial response following first line platinum-taxane based chemotherapy plus bevacizumab, and planned to receive bevacizumab in the maintenance phase.
    E.2.2Secondary objectives of the trial
    1. To determine :
    • time to earliest progression by RECIST or Cancer Antigen-125 (CA-125) or death
    • time from randomization to first subsequent therapy or death (TFST)
    • time from randomization to second progression (PFS2)
    • time from randomization to second subsequent therapy or death (TSST)
    • overall survival (OS)
    2. To assess the safety and tolerability of olaparib maintenance compared to placebo.
    3. To compare the effects of olaparib maintenance compared to placebo on Health-related Quality of Life (HRQoL) and patient reported outcomes (PROs), with consideration of patient preference.
    4. To evaluate the impact of treatment and disease on resource use.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    1. To explore pre planned subgroups analyses of efficacy (PFS1 and OS) based on relevant potential prognostic factors, including stratification factors.
    2. To explore the time to next severe toxicity (grade 4 neutropenia
    lasting > 7 days, grade ≥ 3 febrile neutropenia, grade 4
    thrombocytopenia with bleeding or platelet transfusion, grade ≥ 3 nonhematological
    toxicity) in both arms
    3. To explore the correlation between geriatric assessment and efficacy and tolerance of olaparib versus placebo for patients > 70 years old.
    4. To explore the efficacy of olaparib by assessment of overall survival (OS) adjusting for the impact of spontaneous switching (outside of study design) to Polyadenosine 5’diphosphoribose [poly (ADP ribose)] polymerization (PARP) inhibitors or other potentially active investigational agents.
    5. Biological biomarkers analysis: to determine the frequency of somatic BRCA mutation (sBRCAm) in tumor samples and to compare this with germline BRCA mutation (gBRCAm) status. To determine a HR deficiency signature correlated with olaparib efficacy combined with bevacizumab.
    6. To explore whether resistance mechanisms to olaparib can be identified through analysis of tumor and blood samples – archival tumor and blood sample at baseline (mandatory), tumor biopsy and blood sample on progression (optional).
    7. Future exploratory research into factors that may influence response to study treatment (where response is defined broadly to include efficacy, tolerability or safety) and may be performed on the collected and stored archival tumor samples that were mandatory for entry onto the study or on optional tumor biopsy samples collected during the course of the study.
    8. To collect and store DNA (according to each country’s local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (i.e., distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (optional).
    E.3Principal inclusion criteria
    I-1. Female Patients must be ≥18 years of age.
    I-2. Signed informed consent and ability to comply with treatment and follow-up.
    I-3. Patient with newly diagnosed:
    I-3-1 Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer,
    I-3-2 Histologically confirmed (based on local histopathological findings):
     high grade serous (see appendix 2) or
     high grade endometrioid (see appendix 2) or
     other epithelial non mucinous ovarian cancer in a patient with germline BRCA 1 or 2 deleterious mutation.
    I-3-3 At an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification (see appendix 1).
    I-4. Patients who have completed prior to randomization first line platinum-taxane chemotherapy:
    a. Platinum-taxane based regimen must have consisted of a minimum of 6 treatment cycles and a maximum of 9. However if platinum based therapy must be discontinued early as a result of non hematological toxicity specifically related to the platinum regimen (i.e. neurotoxicity, hypersensitivity etc.), patients must have received a minimum of 4 cycles of the platinum regimen.
    b. Intravenous, intraperitoneal, or neoadjuvant platinum based chemotherapy is allowed; for weekly therapy, three weeks are considered one cycle. Interval debulking is allowed.
    I-5. Patients must have received prior to randomization a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinium-based chemotherapy. Bevacizumab treatment should be planned for maintenance phase.
    I-6. Patients must be prior to randomization without evidence of disease (NED) or in complete response (CR) or partial response (PR) from their first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout their first line treatment and prior to study randomization.
    I-7. Patients must be randomized at least 3 weeks and no more than 9 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from the previous chemotherapy must have resolved to CTC AE grade 1 or better (except alopecia and peripherical neuropathy).
    I-8. Patients must have normal organ and bone marrow function:
    a. Haemoglobin ≥ 10.0 g/dL, with no red blood cells transfusion in the past 28 days
    b. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
    c. Platelet count ≥ 100 x 109/L.
    d. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
    e. Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT)) and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) ≤ 2.5 x ULN, unless liver metastases are present in which case they must be ≤ 5 x ULN.
    f. Serum creatinine ≤ 1.25 x institutional ULN,
    g. Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) ≤1.5 and an Activated ProThrombin Time (aPTT) ≤1.5 x ULN.
    The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or APTT is within therapeutic limits (according to site medical standard). If the patient is on oral anticoagulants, dose has to
    be stable for at least two weeks at the time of randomization.
    h.Urine dipstick for proteinuria < 2+. If urine dipstick is ≥2+, 24-hour urine must demonstrate <1 g of protein in 24 hours.
    I. Normal blood pressure or adequately treated and controlled hypertension (systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg).
    I-9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (see appendix 3)
    I-10. Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.
    I-11. Postmenopausal or evidence of non-childbearing status for women of childbearing potential prior to the first dose of study treatment.
    I-12. For France only: In France, a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of, a social security category.
    E.4Principal exclusion criteria
    -Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).
    -Ovarian tumors of low malignant potential (e.g. borderline tumors), and clear cell, or mucinous carcinoma.
    -Patients with synchronous primary endometrial cancer unless both of the following criteria are met:
    -stage < II,
    -Less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade III endometrial carcinoma.
    OR ≥ 60 years old at the time of diagnosis of endometrial cancer with stage IA grade 1 or 2 endometrioid adenocarcinoma.
    -Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium are not eligible.
    -Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer curatively treated in situ cancer of the cervix, ductal carcinoma in situ .
    Patients with history of primary triple negative breast cancer may be eligible provided they completed their definitive anticancer treatment more than 3 years ago and they remain breast cancer disease free prior to start of study treatment.
    -Patients with myelodysplastic syndrome/acute myeloid leukemia history.
    -Patients having experienced a delay > 2 weeks in the chemotherapy course administration due to prolonged hematological recovery.
    -Patients receiving radiotherapy within 6 weeks prior to study treatment.
    -Major surgery within 4 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
    -Previous allogeneic bone marrow transplant.
    -Any previous treatment with PARP inhibitor, including olaparib.
    -Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period
    -Current or recent (within 10 days prior to randomization) chronic use of aspirin > 325 mg/day.
    -Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.
    -Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.
    -Clinically significant cardiovascular disease, including:
    -Myocardial infarction or unstable angina within ≤ 6 months of randomization,
    -NYH ≥ grade 2 congestive heart failure (CHF),
    -Poorly controlled cardiac arrhythmia despite medication (patients with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
    -Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living [ADL] requiring repair or revision).
    -Previous Cerebro-Vascular Accident, Transient Ischemic Attack or Sub- Arachnoids Hemorrhage within 6 months prior to randomization.
    -History or evidence of hemorrhagic disorders within 6 months prior to randomization.
    -Evidence of bleeding diathesis or significant coagulopathy
    -History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in case of suspected spinal cord compression.
    -History or evidence upon neurological examination of central nervous system disease, unless adequately treated with standard medical therapy .
    -Significant traumatic injury during 4 weeks prior to randomization.
    -Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions healing by secondary intention with no evidence of facial dehiscence or infection are eligible but require 3 weekly wound examinations.
    -History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.
    -Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.
    -Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.
    -Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.
    -Pregnant or lactating women.
    --Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
    -Patients with a known hypersensitivity to olaparib or any of the recipients of the product.
    -Immunocompromised patients, e.g., with known active hepatitis due to risk of transmitting the infection through blood or other body fluids or patients who are known to be serologically positive for human immunodeficiency virus
    E.5 End points
    E.5.1Primary end point(s)
    PFS1 is defined as the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST version 1.1 or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized study treatment or receives another anti-cancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable RECIST assessment. However, if the patient progresses or dies after two or more missed visits, the patient will be censored at the time of the latest evaluable RECIST assessment. If the patient has no evaluable visits or does not have a baseline assessment they will be censored at day 1 unless they die within two visits of baseline.
    The PFS time will always be derived based on imagery assessment dates not visit dates. RECIST assessments contributing towards a particular visit may be performed on different dates. The following rules will be applied:
    • Date of progression will be determined based on the earliest date of the RECIST assessment fulfilling criteria of disease progression.
    • When censoring a patient for PFS the patient will be censored at the latest of the RECIST assessment dates contributing to a particular overall visit assessment.
    The primary analysis will be based on investigator-recorded assessments. An independent central review (ICR) of the radiological scans may be carried out.
    E.5.1.1Timepoint(s) of evaluation of this end point
    PFS1 is defined as the time from randomization until the date of the first objective radiological disease progression according to investigator assessment of RECIST version 1.1 or death
    E.5.2Secondary end point(s)
    Overall Survival (OS)
    Overall survival is defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time to earliest progression by RECIST or CA-125
    Time to earliest progression by RECIST v. 1.1 or CA-125 or death is defined as the time from randomization to the earliest date of RECIST or CA-125 progression or death by any cause. Progression according to CA-125 will be assessed according to GCIG (see appendix 8).
    Patients without a CA-125 progression or a RECIST progression who are still alive at the time of analysis will be censored at their last evaluable RECIST assessment or their last available CA-125 measurement, whichever is the most recent at the time of the analysis. If a patient progresses or dies after two or more missed RECIST and
    CA-125 assessments, then the patient will be censored at the time of their last evaluable assessment. If only one assessment is missing during this period, no censoring is required.

    Second Progression Free Survival (PFS2)
    Time from randomization to second progression is defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the primary variable PFS, or date of death. The date of second progression will be recorded by the investigator and defined according to local standard clinical practice and may involve any of; objective radiological, CA-125 or symptomatic progression or death. Second progression status will be reviewed regularly following the progression event used for the primary variable PFS (PFS1) and recorded. Patients alive and for whom a second disease progression has not been observed should be censored at the last time known to be alive and without a second disease progression, i.e. censored at the latest of the tumor assessment date if the patient has not had a second progression or death).

    Time to start of first subsequent therapy or death (TFST) will be assessed. TFST is defined as the time from the date of randomization to the earliest of the date of anti-cancer therapy start date following study treatment discontinuation, or death. Subsequent therapies intended to control ovarian cancer will be reported. Any patient not known to have died at the time of the analysis and not known to have had a further intervention of this type will be censored at the last known time to have not received subsequent therapy, i.e. the last follow-up visit where this was confirmed.

    Safety and Tolerability
    Safety and tolerability will be assessed in terms of AEs, deaths, laboratory data, vital signs and ECG. AE will be described according to MedDRA terms (version 17.0) and graded according to CTCAE version 4.03. These will be collected for all patients. Appropriate summaries of these data will be presented

    Patient reported outcome variables
    Patient-reported health-related quality of life (HRQoL) will be assessed using the FACT-O questionnaire 24(Basen-Engquist K et al 2001). The FACT-O is composed of the following subscales: physical, social/family, emotional, and functional well-being as well as the additional concerns scales consisting of specific ovarian cancer symptoms.
    The total FACT-O score will be calculated which is made up of the sum of the individual subscale scores: physical well being (PWB), social well being (SWB), emotional well being (EWB) and functional well being (FWB).

    Geriatric assessment
    Geriatric assessment will be assessed using the Geriatric Vulnerability Score (GVS). Further details of the analysis based on the geriatric assessment will be outlined in the SAP.

    frequency and estimates of resource use, including length of stay and number of hospital admissions, will be derived from the resource use information.
    E.5.2.1Timepoint(s) of evaluation of this end point
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of life
    Geriatric assessment
    Genomic and genetic
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA150
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as ‘the last visit of the last patient undergoing the study’.
    The study is expected to start in Quarter 1 2015 and to end by Quarter 1 2022. The study may be terminated at individual centers if the study procedures are not being performed according to GCP, or if recruitment is slow. ARCAGY Research may also terminate the entire study prematurely if concerns for safety arise within this study or in any other study with olaparib.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years7
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 526
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 260
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 762
    F.4.2.2In the whole clinical trial 786
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    according local standard for each institution
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation ENGOT
    G.4.3.4Network Country European Union
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-10-30
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice